ReviewMedicine2025
Mesenchymal tumor-induced Fanconi syndrome: A novel classification of Fanconi syndrome.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleFanconi syndrome (FS) caused by mesenchymal tumors is rarely reported, and these tumors are usually small and difficult to detect. However, if found and removed, the FS can be cured. PATIENT CONCERNS: Five patients were included in this study, and their clinical features, treatments, and prognoses of tumor-induced FS were reviewed and summarized. DIAGNOSES: Mesenchymal tumor-induced FS was diagnosed based on laboratory, imaging, and pathological examinations.
interventionsWe performed tumor resection surgery and administered a symptomatic treatment regimen that included neutral phosphorus solution, calcitriol, calcium, and potassium supplementation, and acidosis correction. OUTCOMES: Two patients were cured, while 3 other patients showed transient symptomatic improvement postoperatively but still required symptomatic treatment due to tumor recurrence. LESSONS: Our case report and literature review demonstrate that mesenchymal tumors should be included in the spectrum of disorders associated with FS and that FS may represent end-stage tumor-induced osteomalacia (TIO) in certain individuals. The diagnosis of FS requires consideration of tumor-induced causes, with early detection and complete resection being crucial for a cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.